Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024年3月6日 - 6:30AM
ビジネスワイヤ(英語)
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering
and developing novel immunological agents to treat various cancers,
today announced that the Compensation Committee of Agenus’ Board of
Directors granted inducement awards to Nils Eckardt, Kent Barnes,
and Brian Greenblatt, in connection with their appointments as
Chief Medical Affairs Officer, Head of Marketing and Sales, and
Vice President Commercial Operations and Business Analytics,
respectively. The Compensation Committee approved the awards
pursuant to Agenus' 2015 Inducement Equity Plan and in accordance
with Nasdaq Listing Rule 5635(c)(4).
The awards to Nils Eckardt consist of (i) options to purchase
100,000 shares of Agenus common stock with a 10-year term, an
exercise price equal to the closing price of Agenus' common stock
on the Grant Date (February 1, 2024), and vesting over four years
in equal annual installments and (ii) 50,000 restricted stock units
that vest over three years in equal annual installments; provided
that each equity award to Nils Eckardt is subject to him
maintaining a service relationship with the company through the
relevant vest date.
The awards to Kent Barnes consist of (i) options to purchase
100,000 shares of Agenus common stock with a 10-year term, an
exercise price equal to the closing price of Agenus' common stock
on the Grant Date (April 1, 2024), and vesting over four years in
equal annual installments and (ii) 100,000 restricted stock units
that vest over three years in equal annual installments; provided
that each equity award to Kent Barnes is subject to him maintaining
a service relationship with the company through the relevant vest
date.
The awards to Brian Greenblatt consist of (i) options to
purchase 75,000 shares of Agenus common stock with a 10-year term,
an exercise price equal to the closing price of Agenus' common
stock on the Grant Date (April 1, 2024), and vesting over four
years in equal annual installments and (ii) 60,000 restricted stock
units that vest over three years in equal annual installments;
provided that each equity award to Brian Greenblatt is subject to
him maintaining a service relationship with the company through the
relevant vest date.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and
infectious diseases with a comprehensive pipeline of immunological
agents. The company’s mission is to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics) and adjuvants
(through SaponiQx). Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and social media channels.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240305957176/en/
Investors 917-362-1370
investor@agenusbio.com
Media 781-674-4784
communications@agenusbio.com
Agenus (NASDAQ:AGEN)
過去 株価チャート
から 4 2024 まで 5 2024
Agenus (NASDAQ:AGEN)
過去 株価チャート
から 5 2023 まで 5 2024